RMD

ResMed Inc. 10-Q Summary: Period Ended December 31, 2001

Business Context and Reporting Period

This is a quarterly report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing devices for sleep-disordered breathing. The reporting period covers the three and six months ended December 31, 2001. The company's principal manufacturing is located in Australia, with major distribution sites in the US, UK, France, Germany, Sweden, and Singapore.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 42% ($14.6 million) for the quarter and 45% ($29.6 million) for the six-month period compared to the prior year. Growth was driven by increased unit sales of flow generators and accessories in domestic and international markets, as well as the acquisition of MAP Medizin-Technologie GmbH.
• Margin Compression: Gross profit margins decreased slightly to 65% (quarter) and 66% (six months) from 67% in the prior year periods. Management attributes this to a shift in geographical sales mix toward the lower-margin domestic market.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 38% for the quarter and 43% for the six months, primarily due to increased personnel and costs associated with MAP operations. R&D expenses increased 44% for the quarter due to new product development and MAP integration.
• Interest Expense: Other income (expense) turned from a net income of $0.7 million to a net expense of $0.9 million for the quarter, largely due to increased interest expense from the convertible debt issued in June 2001.
• Tax Rate: The effective income tax rate declined to approximately 30% from 34.1% in the prior year, benefiting from a reduction in the Australian corporate tax rate and R&D tax deductions.

Guidance, Outlook, and Risks

• Capital Expenditures: The company paid a $2.4 million deposit on a 30-acre site in Sydney, Australia, for a new manufacturing facility expected to be operational in 2003. Total land cost is estimated at $21 million, with building costs estimated at $22.5 million.
• Acquisitions: On November 15, 2001, ResMed acquired Labhardt AG (Swiss distributor) for $5.5 million. Additionally, a $1.4 million contingent payment was made for the prior acquisition of MAP.
• Foreign Exchange Risk: The company faces exposure to currency fluctuations, particularly the Australian dollar and Euro. It utilizes foreign currency call options to hedge these risks. Unrealized gains/losses on these derivatives are marked to market.
• Legal Proceedings: Ongoing patent litigation with Respironics in the US District Court for the Western District of Pennsylvania. The court has granted three partial summary judgment motions for non-infringement in favor of Respironics; ResMed intends to appeal. Additionally, a subsidiary in Germany obtained a favorable judgment against Hofrichter Medizintechnick GmbH, which has been appealed.
• Accounting Changes: The company adopted SFAS 142 (Goodwill) effective July 1, 2001, ceasing the amortization of goodwill and testing it for impairment annually instead. No impairment was identified in the initial assessment.

Investor Verification Checklist

• Verify the sustainability of revenue growth given the shift to lower-margin domestic markets.
• Monitor the outcome of the Respironics patent litigation and potential impact on future revenue.
• Assess the execution risk and capital requirements for the new Sydney manufacturing facility.
• Review the impact of foreign currency fluctuations on future earnings, given the significant hedging program.
• Confirm the integration progress and financial contribution of the Labhardt AG and MAP acquisitions.